Methods: Patients seen between 2008-2013 with a combination of ICD-9 diagnoses of asthma, nonsteroidal anti-inflammatory drugs (NSAID) allergy, and either nasal polyps or chronic rhinosinusitis were identified. A questionnaire to assess AERD-related symptoms was administered via telephone.
Results: 4064 patients had ICD-9 diagnoses of asthma. Of these, 232 (7%) had ICD-9 diagnoses of NSAID allergy and either nasal polyps or chronic rhinosinusitis. One hundred forty-one patients agreed to participate in telephone interviews. The majority was female (82%), with mean age 52 (+/-SD 15). Sixty-five patients were categorized as “likely having AERD” based on reported asthma attacks with NSAID ingestion. The estimated AERD prevalence among asthma patients at Montefiore was 1.6%. Thirty-three patients (51%) with historically-diagnosed AERD reported frequent sinus infections, 31 patients (48%) had ≥1 sinus surgery, and 34 patients (54%) had poor or no sense of smell. Seventy-six patients reporting stomach pain, hives or angioedema, and no asthma symptoms after NSAID ingestion were identified as “not having AERD”
Conclusions: The estimated low AERD prevalence among patients with asthma indicates that AERD is not a simple combination of diagnoses and is likely underdiagnosed. Introducing AERD-specific ICD code could raise awareness about this condition and lead to appropriate treatment choices (aspirin desensitization).